For research use only. Not for therapeutic Use.
KRASG12D-IN-2 (CAT: I040271) is a selective small-molecule inhibitor targeting the KRASG12D mutation, a key oncogenic driver in multiple cancers. This compound demonstrates potent, dose-dependent antitumor efficacy, as evidenced in AsPC-1 xenograft mouse models, where it significantly inhibits tumor growth. KRASG12D-IN-2 is designed to disrupt aberrant KRAS signaling, offering a valuable tool for studying mutant-specific inhibition and tumor regression mechanisms. It supports research into targeted therapies for pancreatic and other KRASG12D-driven malignancies, aiding in the development of precision oncology strategies focused on this challenging and clinically significant mutation.
| Synonyms | 4-[4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-2-[dideuterio-[6-(difluoromethylidene)-2,3,5,7-tetrahydro-1H-pyrrolizin-8-yl]methoxy]-8-fluoropyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-amine |
| Molecular Formula | C34H29D2F4N7O |
| Purity | ≥95% |
| IUPAC Name | 4-[4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-2-[dideuterio-[6-(difluoromethylidene)-2,3,5,7-tetrahydro-1H-pyrrolizin-8-yl]methoxy]-8-fluoropyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-amine |
| InChI | InChI=1S/C34H31F4N7O/c1-2-23-26(35)7-4-18-10-20(39)11-24(27(18)23)29-28(36)30-25(13-40-29)32(44-15-21-5-6-22(16-44)41-21)43-33(42-30)46-17-34-8-3-9-45(34)14-19(12-34)31(37)38/h1,4,7,10-11,13,21-22,41H,3,5-6,8-9,12,14-17,39H2/t21-,22+,34?/i17D2 |
| InChIKey | BXUWTUPVKIWRNH-WBGUKRJMSA-N |
| SMILES | C#CC1=C(C=CC2=CC(=CC(=C21)C3=NC=C4C(=C3F)N=C(N=C4N5CC6CCC(C5)N6)OCC78CCCN7CC(=C(F)F)C8)N)F |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
